Annual
Report 2024
The synergy of engineering and biology – that sets us apart
Our unique approach of combining device technology with biological processes is driving our success and allowing us to set new standards.
From launching a groundbreaking family of measurement modules that close workflow gaps, to integrating multiple tests into a single device for CAR T-cell therapies, we are redefining what is possible in life sciences and diagnostics.
Transforming diagnostics with automation
The field of oncology has undergone a huge transformation in recent years, resulting in a significant increase in survival rates of cancer patients.
Ann Costello, a former Roche executive, shares insights from her +30-year career in the field and talks about how automation, AI, and customer-centric design are redefining the future of diagnostics. She also reveals key success factors for diagnostic device development.
Spatial biology is redrawing the map
Spatial biology technologies are revolutionizing cancer research by allowing us to explore the organization and interaction of cells, tissues, and molecules in unprecedented detail.
Andreas Geipel, Principal System Engineer at HSE•AG, explains what can be achieved with spatial biology – especially in understanding and combating cancer.
Automation is a major driver in personalized medicine
Personalized therapies target the unique genetic makeup of each patient, but they are not widely available due to the high costs involved.
Felix Westhoff, Head of Project and Quality Management at HSE•AG, reveals the benefits of automating production of personalized treatments and what this means for the future of patient care.
Cancer is becoming less scary
The chances of surviving a cancer diagnosis have increased significantly in recent years, thanks to ground-breaking diagnostic techniques and the development of targeted therapies.
Experienced oncologist, Pavel Pisa, M.D., PhD, reveals how in manycases these are transforming cancer from a death sentence into a manageable condition.
Automated sample prep is at the heart of our DNA
Reliable purification of nucleic acids from a wide range of medical and biological samples is a prerequisite for accurate results.
Felix Westhoff, Head of Project and Quality Management at HSE•AG, highlights the benefits of applying established technologies to new areas. He also shares his insights into the current trend in diagnostic assays.
Artificial intelligence: boon or burden?
Artificial intelligence (AI) promises so much yet often fails to deliver the desired answer. Whether AI tools are extremely powerful or completely useless depends on the data available. Without reliable data, AI cannot generate a reliable answer.
Michael Collasius, CEO of HSE•AG, explores where intelligent systems help – and where they still fall short in advancing diagnostics.
Facts and Figures
62 %
previous year: 47 %
13.1 million CHF
80 %
7
80 employees
Our commitment to sustainability
EcoVadis honored us with a bronze medal for our unwavering commitment to sustainability and responsible business practices.
.svg)